Malignant peripheral nerve sheath tumor staging on PET-CT imaging in a patient with neurofibromatosis type I

Abstract

Malignant peripheral nerve sheath tumors can be seen in about 4.6% of neurofibromatosis type I patients. In this rare case, we aimed to emphasize the importance of PET-CT imaging in demonstrating the prevalence of a 24-year-old male patient with neurofibromatosis type I.

Keywords: neurofibromatosis, acquisition mode, lymphadenopathies, necrotic hypermetabolic, left pararectal, hypermetabolic, right hemithorax

Introduction

Malignant peripheral nerve sheath tumor (MPNST) is a rare tumor group seen in neurofibromatosis type I patients. There are few reports on PET-CT imaging of this rare entity in literature. FDG PET-CT is a part of the conventional work-up among a variety of cancer patients. Nevertheless, in certain clinical situations PET-CT may be of great significance, especially as treatment algorithm or differential diagnosis of benign and malignant tumors. In this rare case, we aimed to emphasize the importance of PET-CT imaging in demonstrating the prevalence of a 24-year-old male patient with neurofibromatosis type I.

Case report

A 24-year-old male patient followed up neurofibromatosis type I in bilateral lower extremity was sent to our Nuclear Medicine Department for PET-CT imaging for suspected lung metastasis on radiological imaging. Following 8 hours of fasting, while the patient had a blood glucose level of 79 mg/dL, 8.7 mCi (321.7 MBq) 18F-FDG i.v. was injected. PET-CT scan was obtained 60 min after injection using an integrated scanner (GE Discovery PET-CT 610, US). A whole-body CT scan was performed without intravenous contrast administration with 130 kV, 50 mAs, a pitch of 1.5, a section thickness of 5 mm, and a field of view of 70 cm. A PET scan was performed immediately after an unenhanced CT scan, and acquired from the calvarium to the footwell with a 2.3-min acquisition per bed position using a three-dimensional acquisition mode. Obtained images were evaluated after attenuation correction with low dose non-diagnostic CT. PET-CT imaging demonstrated hypermetabolic (SUVmax: 5.23-10.08) pleural thickening and effusion on the right hemithorax extending to perihepatic region and diaphragmatic crus and several hypermetabolic metastatic nodules with the largest size approximately 3 cm (SUVmax: 15.46) in the basal segment of the left lower lobe of the lung. Bilateral inguinal lymphadenopathies and necrotic hypermetabolic masses (SUVmax: 5.05) with a largest diameter of approximately 9 x 6 cm were observed on the right and left pararectal areas in pelvic region. In addition, lymphedema in both lower extremities, neurofibromatosis masses in the right gluteal region and in soft tissues at different levels in both lower extremities with similar characteristics (SUVmax: 6.48) as pelvic masses were observed (Figure 1).

Discussion

Malignant peripheral nerve sheath tumor (MPNST) constitutes the tumor group, also called neurogenic sarcoma, neurofibrosarcoma, malign neurilemmom, malign schwannoma. Tumors seen in these
group of patients are at worse prognosis due to early onset, central localization, large size, more frequent metastases and recurrences. There are few reports on this rare entity in literature.1-3 In a case report, the authors present a typical case of MPNST in a 36-year-old man with NF type 1, which occurred on the left buttock. A PET-CT showed findings of possible inguinal lymph node metastasis and a lymph node biopsy confirmed the diagnosis.1 In another report the authors presented a clinical case with Von Recklinghausen disease and recurrence of a left dorsal neurofibrosarcoma diagnosed by Positron Emission Tomography with fluorine-18-fluoro- deoxyD-glucose.2 In rare cases, PET-CT has been helpful and guiding in the imaging of the disease and in the staging of the disease. The authors reported the case of a patient with NF1 who developed synchronous malignant peripheral nerve sheath tumors, one with a focus of angiosarcoma.3 In a recent original article on determining whether measurements of 18F-FDG heterogeneity could improve differentiation of benign symptomatic neurofibromas from malignant peripheral nerve sheath tumours (MPNSTs), 18F-FDG PET data from a cohort of 54 patients with neurofibromatosis-1 (NF1), and clinically suspected malignant transformation of neurofibromas into MPNSTs, were included. The authors concluded that 18F-FDG uptake in MPNSTs is higher than benign symptomatic neurofibromas, as defined by SUV parameters, and more heterogeneous, as defined by first- and high-order heterogeneity parameters.4 We believe the current interesting case is important due to the relatively uncommon clinical presentation and the discussion on the utility of 18-FDG PET-CT in this very rare entity.

Acknowledgements

None.

Conflict of interest

Author declares that there is no conflict of interest.

References
